Investment Research and Business Due Diligence
Tuesday, June 18, 2013
SAVOR-TIMI-53 - CV Outcome study on Onglyza fails to Impress - All eyes now on TECOS
AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of
(saxagliptin). In this study of adult patients with type 2 diabetes with either a history of established cardiovascular disease or multiple risk factors,
met the primary safety objective of non inferiority, but did not meet the primary efficacy objective of superiority, for a composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo.
Implications of SAVOR-TIMI-53
Onglyza is a DPP-IV inhibitor and apart from Onglyza there are four other DPP-IV's on the market which includes -
Januvia, Nesina, Tradjenta, Galvus currently on the market.
Currently the DPP-IV take about 12 percent share in the the oral diabetes market. Had Onglyza been able to demonstrate a statistically significant reduction in CV outcome, this would have not only helped Onglyza enhance its market share within the DPP-IV space, but also help the DPP-IV class in further increasing its dominance in the overall oral anti-diabetes market.
These are preliminary data, a detailed analysis which will be potentially presented at ESC, would also be important as it would also provide signals on the other long term safety of the DPP-IV class, especially with regard to the pancreatitis.
Other Ongoing CV outcome studies on DPP-IV inhibitors
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE
Enter your email address:
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)